Merck & Company Inc (MRK)vsMainz Biomed BV (MYNZ)
MRK
Merck & Company Inc
$135.17
-0.59%
HEALTHCARE · Cap: $335.46B
MYNZ
Mainz Biomed BV
$1.43
-2.72%
HEALTHCARE · Cap: $7.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10087029% more annual revenue ($66.57B vs $659,940). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 34/100 (F).
MRK
Avoid34
out of 100
Grade: F
MYNZ
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.9%
Fair Value
$82.46
Current Price
$135.17
$52.71 premium
Intrinsic value data unavailable for MYNZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : MYNZ
The strongest argument for MYNZ centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Return on Equity, Profit Margin, Debt/Equity. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MYNZ carries more volatility with a beta of 0.26 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (34/100 vs 18/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?